TAIPEI, Taiwan & WATERTOWN, Mass.— Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced the promotion of Nikhil Rao, Ph.D., to Chief Commercial Officer. The promotion comes as the company completed the global commercialization of its groundbreaking Microscoop® system, a first-of-its-kind solution for spatial proteomics.
“Nikhil has made an immediate positive impact on our company, helping to scale our commercial organization to sustain our growth and support our customers all over the world,” said Jung-Chi Liao, Ph.D., founder and CEO of Syncell. “I look forward to his continued partnership in advancing new spatial biology and protein solutions that advance biomedical innovation.”
Nikhil Rao joined Syncell in August 2024 as Senior Vice President of Commercial and has quickly built a robust sales, marketing, and service organization to enable Syncell’s rapid global growth. Throughout his distinguished career in the life sciences, he’s focused on advancing commercial adoption of disruptive research tools with a focus on advancements in spatial biology and multiomics. Prior to joining Syncell, Rao held leadership roles at 10x Genomics, where he led the Spatial Biology Business and launched and managed the Visium and Xenium platforms, and Becton, Dickinson & Company, where he launched several single cell transcriptomics products. Rao holds a Ph.D. in Bioengineering from the University of California, San Diego and a B.S. in Chemical & Bimolecular Engineering from The Johns Hopkins University.
“Spatial biology has progressed significantly in recent years, where immunofluorescent markers have been supplemented by multiplexed antibody technologies and advanced laser capture enables researchers to study many more samples from multicellular to single-cell resolution,” said Nikhil Rao, chief commercial officer at Syncell. “Unbiased cellular and subcellular spatial proteomics is the next frontier of biological discovery with Syncell bringing together elements of pathology, microscopy and mass spectrometry into a novel new technology. It’s an honor to be part of the team catalyzing this field and enabling our customers to take their research further.”
About Syncell
Syncell is a commercial stage life science company focused on subcellular protein purification and spatial proteomics analysis. The company was founded in 2020 leveraging technology developed by founder and CEO Jung-Chi Liao at Academia Sinica laboratory in Taiwan. Syncell has commercialized its Microscoop® technology, helping researchers achieve unbiased discovery in spatial proteomics at the disease site, with the ability to accurately discover new protein components from targeted regions of interest. To date, the company has raised $30 million from investors. To learn more, visit www.syncell.com or follow us on Linkedin.
Media Contact
Gwen Gordon
Gwen@gwengordonpr.com
